March 28, 2024

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Kosiborod et al. (Thu,) studied this question.

synapsesocial.com/papers/68e71ec4b6db6435876980af https://doi.org/https://doi.org/10.1056/nejmoa2313917

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity2023 · 1,457 citations
2Dapagliflozin for heart failure according to body mass index: the DELIVER trial2022 · 147 citations
3Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure2021 · 277 citations
4Heart Failure With Preserved Ejection Fraction2023 · 603 citations
5The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.1975 · 1,119 citations

Preguntar a la IA

Me gusta

Guardar